By the end of the Review Course program, participants will be able to: apply new approaches to assessment and diagnosis for common rheumatic diseases in clinical practice; optimize novel therapies and therapeutic strategies for patients with common rheumatic diseases in clinical practice; gain awareness of the pipeline for future developments in the management of common rheumatic diseases.

Refractory Rheumatoid Arthritis – What Does it Mean in 2023?
Maya Buch

This talk will discuss the challenge of defining refractory RA and the current literature on the extent and burden of the condition. The current EULAR definition of ‘Difficult to Treat’ RA that is employed as an overarching term will be summarized and how this fits in with the concept of refractory disease. Clinical trial data on therapeutic options in refractory RA will be presented as will a discussion around drivers of persistent measured disease activity, including pain, that can drive DMARD cycling.

At the end of this session, participants will be able to:

1. Identify patients with refractory rheumatoid arthritis
2. Stratify patients with refractory rheumatoid arthritis
3. Describe optimal treatment approaches for patients with refractory rheumatoid arthritis

CanMEDS roles

1. Medical Expert
2. Scholar

Difficult JIA
Karen Onel

The options for treatment and outcome for children with JIA have improved over time.  However, there are still many questions to answer.

At the end of this session, participants will be able to:

1. Describe optimal treatments for Juvenile Idiopathic Arthritis
2. Identify areas that require further focus
3. Gain awareness of long-term prognosis for children with JIA

CanMEDS roles

1. Medical Expert
2. Health Expert
3. Scholar

Updates in Therapeutics for PsA
Vinod Chandran

This session will briefly cover the principles of management of psoriatic arthritis, recent developments in therapeutics, potential new drugs, and current treatment recommendations.

At the end of this session, participants will be able to:

1. Describe current drugs for PsA and its molecular targets
2. Review novel drugs that may be available in the near future for the management of PsA
3. Identify principles of management of PsA and current treatment recommendations

CanMEDS roles

1. Medical Expert
2. Communicator
3. Collaborator

New Therapeutics in Lupus
Jennifer Reynolds

This session will review several new medications for treatment of lupus and lupus nephritis, and their potential place in treatment algorithms.

At the end of this session, participants will be able to:

1. Evaluate recent lupus therapies’ effectiveness and their studied target subpopulations
2. Identify when to add these medications to the current treatment algorithm
3. Review future medications being studied in SLE and unmet needs for lupus patients

CanMEDS roles

1. Medical Expert
2. Collaborator
3. Health Advocate

Management of Myositis Phenotypes
Ophir Vinik

Utilize clinical-serological-pathological subtypes of inflammatory myopathies to tailor and guide management.

At the end of this session, participants will be able to:

1. Develop approach and recognize pitfalls in diagnosis of inflammatory myopathies
2. Identify key clinical-serological-pathological myositis subtypes
3. Utilize myositis phenotype to guide patient management

CanMEDS roles

1. Medical Expert
2. Collaborator
3. Scholar

Osteoarthritis Update
Tom Appleton

An update on the latest evidence and best practices for managing osteoarthritis in rheumatology.

At the end of this session, participants will be able to:

1. Apply new approaches to assessment and diagnosis for osteoarthritis in clinical practice
2. Optimize novel therapies and therapeutic strategies for patients with osteoarthritis in clinical practice
3. Explain the pipeline for future developments in the management of osteoarthritis

CanMEDS roles

1. Medical Expert
2. Collaborator
3. Health Advocate
4. Scholar

Sports Injuries in Youth
Claire LeBlanc

Five common sport medicine conditions affecting young athletes will be presented in this session, we will discuss approaches to the investigation of these conditions as well as treatment strategies.

At the end of this session, participants will be able to:

1. Describe five common sport medicine conditions affecting youth
2. Explain an approach to investigation of the identified conditions
3. Identify treatment strategies

CanMEDS roles

1. Medical Expert
2. Communicator
3. Collaborator
4. Health Advocate

IgG4 Related Disease
Mollie Carruthers

This session will review the diagnostic pitfalls in IgG4-related disease (IgG4-RD) for the general community rheumatologist as well as first line management.

At the end of this session, participants will be able to:

1. Diagnose IgG4-RD
2. Identify mimickers
3. Explain first line management of IgG4-RD

CanMEDS roles

1. Medical Expert
2. Collaborator
3. Scholar